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Abstract
Background: Eye Movement Desensitization and Reprocessing (EMDR) is an evidence-based treatment for PTSD. However,
it is unclear whether EMDR shows the same effectiveness in patients with substance use disorders (SUD) and comorbid
PTSD. In this trial, we examine the effectiveness of EMDR in reducing PTSD symptoms in patients with SUD and PTSD.
Methods/Design:We conduct a single-blinded RCT among 158 patients with SUD and comorbid PTSD admitted to a
German addiction rehabilitation center specialized for the treatment of patients with SUD and comorbid PTSD. Patients
are randomized to receive either EMDR, added to SUD rehabilitation and non-trauma-focused PTSD treatment (TAU),
or TAU alone. The primary outcome is change from baseline in PTSD symptom severity as measured by the Clinician-
Administered PTSD Scale at 6-month follow-up. Secondary outcomes are change from baseline in substance use,
addiction-related problems, depressive symptoms, dissociative symptoms, emotion dysregulation and quality of life.
Assessments are carried out by blinded raters at admission, at end of treatment, and at 3- and 6-month follow-up. We
expect that EMDR plus TAU will be more effective in reducing PTSD symptoms than TAU alone. Mixed models will be
conducted using an intention-to-treat and per-protocol approach.
Discussion: This study aims to expand the knowledge about the effectiveness of EMDR in patients with SUD and
comorbid PTSD. The expected finding of the superiority of EMDR in reducing PTSD symptoms compared to
non-trauma-focused PTSD treatment may enhance the use of trauma-focused treatment approaches for patients with
SUD and co-morbid PTSD.
Trial registration: German Clinical Trials Register: DRKS00009007; U1111-1172-9213. Retrospectively registered 01 Juni 2016.
Keywords: Posttraumatic stress disorder, Alcohol, Substance abuse, Addiction, Comorbidity, Eye movement desensitization
and reprocessing, Trauma-focused treatment, Exposure-based treatment, Psychotherapy outcome research
Background
Up to 45% of the patients with SUD experience comor-
bid PTSD [1–3], indicating a clear need for PTSD treat-
ment in this population. Although the importance of
comorbid PTSD in the treatment of patients with SUD has
been recognized [4], most SUD inpatient rehabilitation
centers in Germany do not offer integrated treatment for
SUD and PTSD. When an integrated treatment is
offered, non-trauma-focused interventions are predomin-
antly used to address PTSD [5]. This current clinical
practice in routine SUD healthcare is in contrast to the
national and international guidelines [6–8] that recom-
mend trauma-focused treatment for PTSD, which clearly
yields higher effect sizes compared with non-trauma-
focused approaches. However, the evidence base of these
guidelines is built on trials in which patients with PTSD
and comorbid SUD have been almost continuously
excluded [9, 10].
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First evidence exists that trauma-focused treatments,
such as prolonged exposure [11], trauma-focused imagi-
nal exposure [12] and structured writing therapy [13],
may also be effective in patients with PTSD and comor-
bid SUD in reducing PTSD symptoms, although the evi-
dence is not consistent [13–15]. This trials also found
that trauma-focused interventions for patients with SUD
and comorbid PTSD could be applied securely without
compromising substance use outcomes [14, 15]. This is
an important result, because clinicians may hesitate to
use trauma-focused therapy for patients with SUD and
comorbid PTSD, because they might believe that elicit-
ing intense emotions related to the traumatic event
during trauma-focused treatment may increase the risk
for relapse [16, 17]. EMDR is another trauma-focused
treatment that has been shown to be effective in patients
with PTSD alone [6, 18]. So far, no RCT has been
conducted that examined whether EMDR is effective in
reducing PTSD symptoms in patients with SUD and
comorbid PTSD.
Trauma-focused PTSD treatment among patients
with SUD may also effectively reduce SUD symptoms
[19, 20]. Patients with PTSD and SUD report higher
levels of craving in response to trauma-related cues
[21] than patients with PTSD. Therefore, these patients
might be more likely to use substances to regulate
negative affective states associated with PTSD [20, 22,
23]. If negative affective states related to PTSD could
be effectively reduced by trauma-focused treatment,
SUD symptoms might also be reduced.
Research aims and hypothesis
The primary aim of this study is to investigate the effect-
iveness of EMDR, added to SUD rehabilitation and non-
trauma-focused PTSD treatment (TAU), in reducing
PTSD symptom severity at 6-month follow-up compared
with TAU alone in patients with SUD and comorbid
PTSD. We hypothesize that EMDR combined with TAU
will lead to a significantly greater reduction of PTSD
symptoms than TAU alone, when comparing PTSD
symptoms from baseline to 6-month follow-up. As sec-
ondary outcomes, we examine the effectiveness of
EMDR on substance use-related outcomes, depressive
symptoms, dissociative symptoms, emotion dysregula-
tion and quality of life. If this study shows that EMDR
can be used effectively in patients with SUD and comor-
bid PTSD, the results of this RCT might encourage a
more frequent use of evidence-based trauma-focused
treatments for patients with SUD and comorbid PTSD.
Methods
Design and study setting
This study is a rater-blinded 2-arms RCT. Assessments
are scheduled pre-treatment (T0), post-treatment (T1),
at 3-month (T2) and at 6-month (T3) follow-up. Partici-
pants are randomly assigned to either the EMDR plus
TAU group or the TAU group. Data is assessed at an in-
patient rehabilitation center in Germany (AHG Clinic
Dormagen). This center is specialized for the treatment
of patients with SUD (primarily alcohol use disorders)
and comorbid PTSD. The study is coordinated by a
research team of the Center for Interdisciplinary
Addiction Research (CIAR), University Medical Center
Hamburg-Eppendorf, Germany. The coordinating site is
responsible for the study design, the training of the
personnel involved in the data collection, the prepar-
ation and supply of all study documents, study monitor-
ing, study supervision, data management and analysis,
and reporting of the study results.
Participants
We plan to recruit 158 adult patients with SUD and co-
morbid PTSD attending inpatient rehabilitation treat-
ment from September 2015 to December 2017.
Inclusion criteria are (1) age between 18 and 65 years;
(2) DSM-5 diagnosis of a substance use disorder [24]; (3)
DSM-5 diagnosis of PTSD or subsyndromal PTSD
(criteria A and B and at least one of the criteria C to E)
[18]; (4) capable to comprehend and speak German; (5)
informed consent to participate in the study. Exclusion
criteria are (1) severe dissociative symptoms according
to the Dissociative Experience Scale [25] (total score >
40); (2) acute suicidality; (3) acute psychotic symptoms;
and (4) severe cognitive impairments.
Interventions
All patients included in this study participate in the
usual treatment (TAU) of the SUD rehabilitation center
provided for patients with SUD and comorbid PTSD.
TAU includes SUD rehabilitation and non-trauma-
focused PTSD treatment. TAU is present-focused and
includes the provision of knowledge, techniques and
skills to better cope with PTSD symptoms and to pre-
vent SUD relapse (psychoeducation about PTSD and
SUD; resource activation, e.g. establishing positive activ-
ities; imaginative exercises [26]; acceptance- and
mindfulness-oriented skills [27]; elements of Seeking
Safety [28], non-trauma-focused CBT). A treatment
protocol was created prior to the start of the study that
defines the intervention elements of the non-trauma-
focused treatment. No processing of traumatic memories
takes place in the TAU condition.
All study participants receive two 90-min and two 60-
min non-trauma-focused group therapy sessions per
week. In addition to the non-trauma-focused group
therapy, participants randomized to the TAU group
additionally receive one 50-min individual non-trauma-
focused therapy session per week; participants randomized
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to the EMDR group receive one 50-min individual EMDR
session per week. During an EMDR session, the patient
focuses on a traumatic experience while simultaneously
focusing on an external bilateral stimulus [29]. EMDR
treatment follows standard EMDR protocols for process-
ing memories of traumatic or stressful life events [30].
Measures
Diagnoses of SUD and PTSD
To assess DSM-5 diagnoses of SUD and PTSD, all
patients receive a semi-structured face-to-face interview
at baseline (T0). The diagnosis of SUD is confirmed
using the SUD section of the International Diagnostic
Checklists for DSM-IV (IDCL) [31], adapted according
to the changed SUD criteria in DSM-V. The IDCL is an
established method for the assessment of psychiatric
diagnoses. Studies have indicated good clinical practic-
ability and satisfactory to excellent inter-rater and
test-retest reliability [31, 32].
The diagnosis of PTSD is confirmed using the
Clinician-Administered PTSD Scale (CAPS) [33, 34] for
DSM-V [33, 34], which is an updated version of the
CAPS for DSM-IV. The CAPS is considered the gold
standard for PTSD assessment [35, 36]. The psychomet-
ric properties of the CAPS-IV have been reviewed [35]
and indicate excellent convergent and discriminant val-
idity, diagnostic utility, and sensitivity to clinical change.
Primary outcome
The primary outcome, change from baseline in PTSD
symptom severity, is assessed using the CAPS for DSM-
V [33, 34]. The interviewer evaluates the severity of each
of the 20 DSM-V PTSD symptoms, based on a com-
bined evaluation of the frequency and intensity on
Likert-type scales (0 = asymptomatic, 1 =mild/subthresh-
old, 2 = moderate PTSD/above threshold, 3 = severe/
markedly increased, 4 = extreme). The 20 DSM-5
PTSD symptom severity scores are then summed up
to derive a total severity score, ranging from 0 to 80.
A change of 15 points on the CAPS is considered
clinically significant [35].
Seconday outcomes
Secondary outcomes include change from baseline in
severity of substance use, addiction-related problems,
dissociative symptoms, depressive symptoms, emotion
dysregulation and quality of life (Table 1).
Change from baseline in severity of substance use is
measured by the Alcohol Use Disorder Identification
Test (AUDIT) [37, 38] or the Drug Use Disorder Identi-
fication Test (DUDIT) [39, 40], respectively, depending
on the type of the patients’ primary substance depend-
ence. As additional substance-related outcomes, the
mean amount of substance use per day and the number
of non-consuming days within the last month is mea-
sured with the Timeline Follow Back (TLFB) [41].
Changes in addiction-related problems are assessed by
the Addiction Severity Index-Lite (ASI-Lite) [42].
Change in dissociative symptoms (Dissociative Experi-
ences Scale, DES) [25], depressive symptoms (Beck
Depression Inventory-II, BDI-II) [43], emotion dysregu-
lation (Difficulties in Emotion Regulation Scale, DERS)
[44] and quality of life (Short-Form 12-Item Health
Survey, SF-12) [45] are also assessed. The type and
severity of early traumatic experiences are measured
using the Childhood Trauma Questionnaire (CTQ) [46].
Sociodemographic data of the patients are measured by
an interview using a sheet designed according to the
documentation standards for the evaluation of addiction
treatment [47].
Serious Adverse Events (SAEs; hospitalization, life-
threatening event, disability or permanent damage,
death) are measured by SAE Reporting Forms (date; ini-
tials of reporting person; participant study number and
participant date of birth; SAE description; start date and
duration of event; action required; action with regard to
intervention; date of last intervention session; causality
to intervention or assessment).
Study procedure
At the patients’ admission to the rehabilitation center, a
clinical psychologist informs the patient about the study
and screens the patient according to the inclusion and
exclusion study criteria. Patients that are potentially eli-
gible for the study and consent to participate will receive
the baseline assessment (T0) within the first days after
admission (Fig. 1). If all inclusion and no exclusion
criteria are fulfilled, the patient will be randomized to
one of the two study arms. Additional data assessments
are conducted at end of treatment (T1), as well as at
3-months and 6-months follow-up (T2 and T3, respect-
ively). The interviews at T0 and T1 are conducted face-
to-face, the interviews at T2 and T3 are conducted by
telephone. To promote participant retention and
complete follow-up, participants will be contacted sev-
eral times between the assessments. The coordinating
study team monitors the study procedure and traces
back potential Serious Adverse Events during the study.
Sample size calculation
Based on the results of the power analysis of a first RCT
examining the effects of a trauma-focused PTSD treatment
plus usual substance use treatment vs. usual substance use
treatment alone in patients with PTSD and SUD [11], using
the Clinician-Administered PTSD Scale (CAPS) as primary
outcome, a sample size of 88 participants is required to
achieve 80% power to detect a clinical significant difference
of 15 points (SD= 25) in PTSD symptoms at 6-months
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follow-up, using mixed models with a .05 α-level of signifi-
cance. In line with the dropout rates reported in previous
intervention studies using rehabilitation inpatients [48, 49], a
dropout rate of 40% is expected at 6-month follow-up. Con-
sequently, we aim to include 158 participants in our study.
Statistical analysis
Summary tables will be provided for all baseline, end of
treatment and follow-up variables. Data will be summa-
rized using frequency tables and descriptive statistics
(mean, standard deviation, number and percentages of
cases). Intention-to-treat and per-protocol analyses will
be conducted for all outcomes. Missing data will be
imputed using multiple imputation or a similar strategy.
To test the hypothesis that EMDR plus TAU will more
greatly reduce PTSD symptoms than TAU alone, a linear
mixed model will be calculated. Changes in PTSD symp-
tom severity at 6-month follow-up as measured by the
CAPS will be the primary outcome of the study and will
be compared between the EMDR plus TAU and TAU
group. The analysis will be adjusted for covariates that
might be unbalanced between the groups (e.g., sex, type
of trauma, treatment time spent in rehabilitation center),
as well as for different baseline CAPS scores. The same
procedure will be applied for secondary outcomes.
Methods to protect against sources of bias
Randomization and allocation
All patients eligible for the study and providing written
consent are randomized to an EMDR or a TAU group in
a ratio of 1:1. The generation of the randomization
sequence took place prior to the recruitment of partici-
pants and was conducted by a researcher of the coordin-
ating site uninvolved in the data assessments of the
study (AL). The list for the random assignment of
patients to the two treatment arms was generated by the
Table 1 Measures and assessment points used in the study
Variable Measure Assessment method T0 Baseline T1 Post treatment T2 3 months T3 6 months
SUD diagnosis IDCL [31] interview x x x x
PTSD diagnosis CAPS [33] interview x x x x
PTSD symptoms CAPS [33] interview x x x x
Early traumatic experiences CTQ [46] self-report x x x x
Substance use AUDIT [37]/DUDIT [40] TLFB [41] interview x x x x
Addiction-related problems ASI-Lite [42] interview x x x x
Dissociative symptoms DES [25] self-report x x x x
Depressive symptoms BDI-II [43] self-report x x x x
Emotion dysregulation DERS [44] self-report x x x x
Quality of life SF-12 [45] self-report x x x x
Safety SAE Report Form self-report —————————————— x x
Notes. IDCL International Diagnostic Checklists. CAPS Clinician-Administered PTSD Scale. CTQ Childhood Trauma Questionnaire. AUDIT Alcohol Use Disorders
Identification Test. DUDIT Drug Use Disorders Identification Test. TLFB Timeline Follow Back. ASI-Lite Addiction Severity Index-Lite. DES Dissociative Experience
Scale. BDI-II Beck Depression Inventory-II. DERS Difficulties in Emotion Regulation Scale. SF-12 Short-Form 12-Item Health Survey. SAE Serious Adverse Event
Fig. 1 Participant flow diagram
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randomization software DatInf RandList Version 1.2
using permuted blocks of random sizes between 4 and
10. Each random number is separately stored in sequen-
tially numbered, opaque and sealed envelopes. After the
eligibility of a patient for the study has been ensured, the
patient is included in the study and the next available
randomization number is assigned to the patient in an
ascending order.
Blinding
Study personnel involved in the data assessment of the
study are blinded to the patients’ treatment assignment.
The clinical psychotherapists that deliver the study treat-
ment are not blinded and are therefore uninvolved in
the patients’ data assessments related to this study. Data
analysts are blinded to group allocation.
Treatment fidelity
All psychotherapists involved in this study regularly work
as psychotherapists in the rehabilitation center at which
the study is conducted. They were trained in SUD re-
habilitation and non-trauma-focused PTSD treatment and
completed the EMDR Basic Training program (see http://
www.emdr-europe.org/info.asp?CategoryID=83). All treat-
ments are conducted in line with the respective treatment
protocols (see description of interventions). All therapists
are supervised by certified EMDR consultants or trainers
of EMDR Europe (LCF, PL, AH) during the treatment
phase of the study.
Psychotherapists document the content of each indi-
vidual treatment session in a treatment log, which is
monitored by the coordinating site. Out of all individual
treatment sessions, 15% randomly chosen videotaped
sessions of each of the two treatment groups are rated
for treatment fidelity (compliance with the treatment
manual). EMDR treatment adherence is evaluated and
monitored by certified EMDR consultants or trainers
(LCF, PL, AH) using the EMDR Implementation Treat-
ment Fidelity Scale [50]. Therapist adherence for
individual SUD rehabilitation and non-trauma-focused
PTSD treatment is evaluated and monitored over the
course of study by trained raters of the coordinating site.
Data assessment fidelity
The personnel involved in data collection (psychology
students with at least BSc level) received a 1-day training
by the coordinating site prior to the start of the study.
The coordinating site monitors the conduction of the
data assessments and supervises (AL) the personnel in-
volved in data collection throughout the study. 15% of
the CAPS interviews are reassessed by a second inter-
viewer to establish inter-rater reliability of the PTSD
diagnosis and symptom severity. If reliability is low, the
interviewers receive additional training. To improve data
entry accuracy, all data sheets are entered by using a
data scanner. Data entries are checked by data manage-
ment personnel for correctness.
Ethical and safety issues
The Ethics Committee of the Medical Council of Ham-
burg (PV4853) and the Ethics Committee of the Medical
Council of Nordrhein (2015233) approved the trial prior
to the start of the study. Before patients are included in
the study, they are informed about the aims and the de-
sign of the study including randomization and the possi-
bility of ending their participation at any time without
disadvantages. Potential study participants must provide
written informed consent before they can be included in
the study. Personal information about potential and en-
rolled participants will be collected and stored separately
from other study data and will be only accessible for the
assessors that contact the participants for data assess-
ment. The study dataset does not include personal infor-
mation and will be analyzed by the coordinating study
site. Throughout the study, the standard safety proce-
dures of the inpatient rehabilitation center at which the
patients of this study are treated are followed. SAEs are
continuously documented throughout the study. SAEs
are reported to the coordinating site within 24 h. In case
of an unexpected SAE (e.g., life-threatening event, per-
manent damage or death) over the course of the study,
the coordinating site will alert the principal investigator
(IS) who will report the SAE to the local ethics commit-
tee. The ethics committee and the study team will then
decide in accordance with the best interest of the patient
if the study procedures are continued or terminated.
Discussion
This is the first RCT that examines the effectiveness of
EMDR combined with TAU (SUD rehabilitation and
non-trauma-focused PTSD treatment), in reducing
PTSD symptoms in patients with SUD and comorbid
PTSD, compared with TAU alone. To test the effective-
ness of EMDR within this patient group is crucial, be-
cause patients with SUD and comorbid PTSD have been
excluded from most clinical trials of trauma-focused in-
terventions for patients with PTSD so far [51]. Conse-
quently, there is limited evidence that EDMR is effective
in this patient group. As a secondary outcome, we also
examine the effectiveness of EMDR on substance use.
As patients may use substances to regulate PTSD-
related symptoms [12, 52], it could be expected that
trauma-focused treatment might also reduce SUD
symptoms.
Strengths and limitations
A strength of this study is that we will be able to include
a sufficient sample size in our study to detect group
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differences between the EMDR plus TAU and the TAU
group. However, we expect a high drop-out rate in our
sample of patients with comorbid mental disorders. The
expected high drop-out rate might complicate the inter-
pretation of the study results. A strength of this study
might be that the patients included in this study live in
various parts of Germany, represent a great variety of
their sociodemographic backgrounds and were exposed
to different types of traumatic experiences. This may in-
crease the generalizability of our results. On the other
hand, we exclude patients that are younger than 18 or
older than 65 years; don’t speak German; present acute
suicidal, psychotic or severe dissociative symptoms; or
show severely cognitive impairment. The study findings
might not be generalized to these populations of patients
with SUD and PTSD.
In summary, the primary aim of this study is to inves-
tigate the effectiveness of EMDR, added to usual SUD
rehabilitation and non-trauma-focused PTSD treatment
(TAU), in reducing PTSD symptoms, compared with
TAU alone. If this RCT proves that EMDR is effective in
patients with SUD and comorbid PTSD, the results of
this RCT may encourage a more frequent use of
evidence-based trauma-focused approaches in routine
treatment of patients with SUD and comorbid PTSD.
Trial status
We are recruiting patients and started with data collection.
The first patient was enrolled in September 2015.
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